Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics

Relief Therapeutics Holding AG RLFTF and Acer Therapeutics Inc ACER have entered into a Collaboration and License Agreement for worldwide development and commercialization of ACER-001 for urea cycle disorders (UCDs) and maple syrup urine diseases (MSUD).

  • ACER-001 is a proprietary powder formulation of sodium phenylbutyrate designed to be both taste-masked and immediate release.
  • Acer will receive an approximately $10 million cash payment.
  • Relief will also pay Acer up to $20 million in U.S. development and commercial launch costs for the above indications.
  • Acer will retain development and commercialization rights in the U.S., Canada, Brazil, Turkey, and Japan.
  • Both the companies will split net profits from Acer’s territories 60:40 in favor of Relief.
  • Besides, Relief has licensed the rest of the world’s rights, where Acer will receive from Relief a 15% revenue royalty.
  • Acer may also receive $6 million in development milestone payments following the first European marketing approvals for UCDs and MSUD.
  • An ACER-001 pre-NDA meeting with the FDA is scheduled for the second quarter of 2021.
  • Price Action: ACER shares are up 20.8% at $4.18 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsGeneralurea cycle disorders
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!